Ambrx Biopharma Inc. (AMAM)
Ambrx Biopharma Statistics
Share Statistics
Ambrx Biopharma has 63.29M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 63.29M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 21.92M |
| Failed to Deliver (FTD) Shares | 848 |
| FTD / Avg. Volume | 0.04% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -1.12 and the forward PE ratio is null. Ambrx Biopharma's PEG ratio is 0.03.
| PE Ratio | -1.12 |
| Forward PE | n/a |
| PS Ratio | 11.84 |
| Forward PS | n/a |
| PB Ratio | 0.74 |
| P/FCF Ratio | -1.26 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Ambrx Biopharma has an Enterprise Value (EV) of 44M.
| EV / Sales | 5.94 |
| EV / EBITDA | -0.79 |
| EV / EBIT | -0.64 |
| EV / FCF | -0.63 |
Financial Position
The company has a current ratio of 5.44, with a Debt / Equity ratio of 0.1.
| Current Ratio | 5.44 |
| Quick Ratio | 5.21 |
| Debt / Equity | 0.1 |
| Debt / EBITDA | -0.21 |
| Debt / FCF | -0.17 |
| Interest Coverage | -58.97 |
Financial Efficiency
Return on Equity is -66.18% and Return on Invested Capital is -45.09%.
| Return on Equity | -66.18% |
| Return on Assets | -53.07% |
| Return on Invested Capital | -45.09% |
| Revenue Per Employee | $85.08K |
| Profits Per Employee | $-896.51K |
| Employee Count | 87 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1.94M |
| Effective Tax Rate | -2.55% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is -2.36, so Ambrx Biopharma's price volatility has been lower than the market average.
| Beta | -2.36 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 25.33 |
| 200-Day Moving Average | 15.99 |
| Relative Strength Index (RSI) | 82.2 |
| Average Volume (20 Days) | 1.94M |
Income Statement
In the last 12 months, Ambrx Biopharma had revenue of 7.4M and earned -78M in profits. Earnings per share was -2.02.
| Revenue | 7.4M |
| Gross Profit | 7.4M |
| Operating Income | -57.08M |
| Net Income | -78M |
| EBITDA | -55.79M |
| EBIT | -64.46M |
| Earnings Per Share (EPS) | -2.02 |
Balance Sheet
The company has 55.61M in cash and 11.98M in debt, giving a net cash position of 43.63M.
| Cash & Cash Equivalents | 55.61M |
| Total Debt | 11.98M |
| Net Cash | 43.63M |
| Retained Earnings | -291.63M |
| Total Assets | 271.5M |
| Working Capital | 215.55M |
Cash Flow
In the last 12 months, operating cash flow was -68.67M and capital expenditures -1.05M, giving a free cash flow of -69.73M.
| Operating Cash Flow | -68.67M |
| Capital Expenditures | -1.05M |
| Free Cash Flow | -69.73M |
| FCF Per Share | -1.81 |
Margins
Gross margin is 100%, with operating and profit margins of -771.16% and -1053.72%.
| Gross Margin | 100% |
| Operating Margin | -771.16% |
| Pretax Margin | -1027.55% |
| Profit Margin | -1053.72% |
| EBITDA Margin | -753.69% |
| EBIT Margin | -771.16% |
| FCF Margin | -942.03% |
Dividends & Yields
AMAM does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -89% |
| FCF Yield | -79.57% |
Analyst Forecast
Currently there are no analyst rating for AMAM.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | 34.85 |
| Piotroski F-Score | 2 |